Heidi Wang

Heidi Wang serves as Chief Executive Officer at OBI Pharma, Inc. since June 2023 and has been a Mentor for Taiwan Innovative Drug Industry since August 2022. With nearly 30 years of extensive experience at Bristol-Myers Squibb from January 1994 to June 2023, Heidi held multiple leadership roles including Therapeutic Area Head for Oncology and Vice President of Global Regulatory Strategy and Policy. Key responsibilities included overseeing international market strategies, FDA engagements, and regulatory submissions across various therapeutic areas such as virology and oncology. Heidi's educational background includes postdoctoral training at Cold Spring Harbor Laboratory and advanced degrees in Molecular Biology and Virology from the University of Notre Dame, complemented by a Bachelor’s degree in Biology from Fu-Jen University.